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ABSTRACT 
BACKGROUND:  Acute pancreatitis a common complication of endoscopic 
retrograde cholangiopancreatography (ERCP), and the benefit of pharmacologic 
treatment ofthe condition is unclear. Although prophylactic use of gabexate mesylate 
(GM) for the reduction of pancreatic injury after ERCP has been evaluated, uncer- 
tainty remains regarding the effectiveness of GM treatment i  post-ERCP pancreatitis 
(PEP). 
OBJECT IVE:  The aim of this study was to determine through systematic review 
and meta-analysis the effectiveness and tolerability of GM in the prophylaxis of PEE 
METHODS:  MEDLINE (January 1966 July 2007), EMBASE (january 1966 
July 2007), the Cochrane Controlled Trials Register on The Cochrane Library (Issue 2, 
2007), and the China Biological Medicine Database (January 1978 July 2007) were 
searched. We used the method recommended by The Cochrane Collaboration to 
perform a systematic review and meta-analysis of randomized controlled trials (RCTs) 
of GM in the prevention of PEP. 
RESULTS:  Of the 38 studies identified, 31 were excluded for the following rea- 
sons: they were reviews or editorials (9 articles); were meta-analyses (4); had differ- 
ences in cointerventions (4); were nonrandomized controlled trials or had incorrect ran- 
domization (4); were repeat publications (2); lacked a placebo group (1); or other (7). 
Seven RCTs, totaling 2883 patients, conducted in a variety of languages were in- 
cluded in the meta-analysis. When the RCTs were analyzed, odds ratios for GM were 
0.65 (95% CI, 0.36 1.18; P 0.16) for PER 1.90 (95% CI, 0.54 6.65; P 0.32) 
for severe PEP, 0.55 (95% CI, 0.17 1.77; P 0.32) for the case-fatality ratio 
of PEP, 0.88 (95% CI, 0.74 1.05; P 0.16) for post-ERCP hyperamylasemia, and 
0.78 (95% CI, 0.49 1.25; P 0.30) for post-ERCP abdominal pain. No evidence of 
publication bias was found. 
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CONCLUSIONS:  No beneficial effects of GM on acute pancreatitis, the PEP 
mortality rate, or post-ERCP abdominal pain or hyperamylasemia were found; there- 
fore, GM cannot be recommended for the prophylaxis of PEP. (Curr Ther Res Clin Exp. 
2008;69:288 304) © 2008 Excerpta Medica Inc. 
KEY WORDS:  gabexate mesylate, post-endoscopic retrograde cholangiopancre- 
atography pancreatitis, prevention, randomized controlled trial, meta-analysis. 
INTRODUCTION 
Three meta-analyses published in 20071,2 and 20003 evaluated randomized controlled 
trials (RCTs) comparing abexate mesylate (GM) with placebo. These studies as- 
sessed prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) 
pancreatitis (PEP), post-ERCP hyperamylasemia, post-ERCP abdominal pain, and 
the case-fatality ratio of PEE One review 1examined 4 RCTs published as full articles 
in peer-reviewed journals between 1996 and 2006 in 2 different countries. These 
studies included patients with high, average, and low risk for PEE The studies found 
that in patients with PEP, GM did not prevent pancreatic injury after ERCE In 2000, 
a meta-analysis 3 including 6 studies reported that patients who received GM after 
ERCP had PEP at an occurrence rate of 1.6% while 6.5% patients in the placebo 
group had PEE Therefore, they concluded that GM use was associated with a signifi- 
cant reduction of PEP (P < 0.001). When they updated the meta-analysis in 2007, 2 
they came to an opposite conclusion. 
ERCP is an important procedure for the diagnosis and treatment of several biliary 
and pancreatic onditions. 4 However, ERCP can also cause acute pancreatitis and 
result in significant morbidity and mortality. 4,5 Depending on the definition used, 
it has been reported that the incidence of PEP was 1% to 40%, whereas post-ERCP 
hyperamylasemia w s found to occur in up to 70% of patients. 6 Although most cases 
(90%) of PEP were mild, 10% of patients developed severe pancreatitis, a condition 
that can result in prolonged hospitalization and increased risk of mortality. 4 
Protease activation is recognized as the key event in the pathogenesis of acute 
pancreatitis; agents that inhibit proteolytic activity were assessed. 7 13 Several stud- 
ies 8,n,13 found that GM was effective in reducing the incidence of PEP; however, 
other studies 9,1°,12 did not find any benefit of GM therapy. The purpose of this study 
was to update previously published meta-analyses 1 3with 3 trials 7'12'13 not previously 
included. 
METHODS 
SELECT ION CRITERIA  
MEDLINE (January 1966 July 2007), EMBASE (January 1966 July 2007), the 
Cochrane Controlled Trials Register on The Cochrane Library (Issue 2, 2007), and 
the China Biological Medicine Datadase (CBMdisc) (January 1978 July 2007) were 
searched using the xploded (exp) medical subject heading terms exp pancreatitis OR 
exp post-ERCP pancreatitis AND the exploded terms gabexate and FOY, and by limiting 
the search to reports of clinical trials in human patients. The search was performed by 
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database specialty personnel. Reference lists of pertinent reviews and retrieved articles 
were also checked to identify additional studies. In addition, we attempted to find 
data from poster presentations and by consulting several experts in the field; however, 
these methods yielded no additional information. 
In the systematic review, the following inclusion criteria were established: (1) each 
trial should be a prospective clinical RCT; (2) the patient population should be aged 
> 18 years; (3) the patients were to be scheduled to undergo ERCP and/or endoscopic 
sphincterotomy; (4) randomized comparisons of GM versus placebo or blank control 
should have been included, regardless of the initial time of treatment, treatment 
duration, dose, and administration route of the drug; and (5) cointerventions (includ- 
ing treating complications) were allowed if administered equally to all intervention 
groups. Two independent reviewers (M.-H.Z. and J.-L.B.) used these criteria to review 
each article identified. 
A study was excluded if: (1) it was quasi-randomized or nonrandomized; (2) the 
patients had active acute pancreatitis, chronic pancreatitis, pancreatic ancer, or can- 
cer of the papilla of Vater; (3) there were difterences in the cointerventions between 
intervention arms; or (4) the report was repetitive (if > 1 version of the same study was 
retrieved, only the most recent was used). 
DATA EXTRACTION 
The 2 reviewers independently extracted data from each matching study using 
a standardized form. To reduce bias, 1 of the reviewers (M.-H.Z.) was blinded to 
the source of the publication and to the authors' names. Inconsistencies between 
reviewers' data were resolved through discussion until a consensus was reached. 
Each RCT was scored for quality to assess validity using the Jadad scoring system, 14 
which is used to evaluate studies based on randomization, blinding, and description 
of withdrawals and dropouts. 15 If the Jadad score of a study was >3, it was consid- 
ered a high-quality study. 16 The extracted ata included characteristics of the trial, 
patients, interventions, and outcomes (including 3 primary outcomes [PEP, severe 
PEP 6, and the case-fatality ratio of PEP] and 2 secondary outcomes [post-ERCP hy- 
peramylasemia and abdominal pain]). Trial characteristics ollected were the country 
of origin, methodologic quality, sample size calculations, and study setting. Patient 
characteristics ollected were inclusion and exclusion criteria, mean age of included 
patients, proportion of men, etiology, number of patients, and number and reasons for 
dropouts and withdrawals. 
STAT IST ICAL  ANALYS IS  
Meta-analysis was performed according to recommendations from The Cochrane 
Collaboration 17and the quality of reporting of meta-analyses guidelines. 18 The eftect 
measures estimated were odds ratio (OR) for dichotomous data and weighted mean 
difterence for continuous data, both reported with 95 % CIs. The OR represented the 
odds of an adverse vent (AE) occurring in the GM group compared with the placebo 
group. An OR of <1 favored the GM group. The point estimate of the OR was con- 
sidered statistically significant at P < 0.05 if the 95% CI did not include the value 1. 
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Studies that contained a zero in 1 cell for the number of events of interest in 1 of the 
2 groups resulted in problems with the computation ofratio measurement; therefore, on the 
recommendation of a statistician, a value of 0.5 was added in both groups for those studies. 
Heterogeneity was evaluated using the Z 2 test. P < 0.1 was considered significant 
for heterogeneity. Fixed-effect models were used throughout, unless statistical hetero- 
geneity was significant, in which case a random-effects model was used. 
Analysis was performed using the statistical software Intercooled Stata version 8.2 
for Windows (Stata Corp., College Station, Texas) and Review Manager version 4.2 
(The Cochrane Collaboration, Software Update, Oxford, UK). 
RESULTS 
The search strategy initially generated 3 1 studies, and 7 additional studies were iden- 
tified from the reference lists of pertinent reviews and retrieved articles (Figure 1). 
Three studies 19 21 were excluded because they were not RCTs. One study 22 was ex- 
cluded because it compared the effect of a short (6-hour) versus a long (12-hour) infu- 
sion and because a placebo group was lacking. One study 23 was excluded because of 
its incorrect randomization method and different cointerventions. Two articles 24,25 
reported > 1 version of the same study, and 4 meta-analyses 1 3,26 and 9 reviews were ex- 
cluded. Eleven additional studies were excluded ue to differences in cointerventions (3); 
MEDLINE (January 1966-July 2007) 
EMBASE (January 1966-July 2007) 
Cochrane Controlled Trials Register (Issue 2, 2007) 
CBMdisc (January 1978-July 2007) 
Potentially appropriate trials to 
be included in meta-analysis 
(n = 31) 
1" 
Accessed trials (n = 38) 
Randomized controlled trials 
included in meta-analysis 
(n = 7) 
Additional studies identified from the 
reference lists of pertinent reviews and 
retrieved articles (n = 7) 
Excluded (n = 31) 
Reviews or editorials (9) 
Meta-analysis (4) 
Difference in cointerventions (4) 
Nonrandomized controlled trial 
or incorrect randomization (4) 
Repeat publication (2) 
Placebo group lacking (1) 
Other reasons (7) 
Figure 1. Identification of eligible randomized controlled trials. CBMdisc = China Bio- 
logical Medicine Database. 
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incorrect randomization (1); and other reasons (7). Thus, 7 RCTs satisfied all of the 
inclusion criteria (Tables 1 and ll). 
PRIMARY OUTCOMES 
In this meta-analysis, PEP (either general PEP or severe PEP 6) was the primary 
outcome. General PEP was found in 6 of the RCTs. 8 13 These trials included 2827 pa- 
tients, with 151 patients (5.3%) having PEE Of the patients with PEP, 68 were 
treated with GM and 83 received placebo. There was significant heterogeneity among 
these studies (Z 2 13.94, degree of freedom [di] 5; P 0.02). However, analysis by 
random-effects model indicated a DerSimonian and Laird (DL) random-effect pooled 
OR of 0.65 (95% CI, 0.36 1.18; P 0.16), with no significant association between 
the use of GM and the reduction of PEP (Figure 2, Table l l l).  When stratified by 
the duration of treatment (group 1, >6 hours; group 2, <6 hours), there was no sig- 
nificant reduction in PEP in either group 1 (DL random-effect pooled OR, 0.63 
[95% CI, 0.30 1.33]; P 0.23) (Figure 3A) or group 2 (DL random-effect pooled 
OR, 0.64 [95% CI, 0.14 2.92]; P 0.57) (Figure 3B). There was significant hetero- 
geneity in both group 1 (Z 2 9.53, df 3; P 0.02) (Figure 3A) and group 2 (Z 2 
3.99, df 1; P 0.05) (Figure 3B). 
Severe PEP was reported in 4 trials 9,1°,12,13 that included 2216 patients, 10 
(0.5%) of whom had severe PEP (7 in the GM treatment group and 3 in the pla- 
cebo group). The Q test of heterogeneity between studies was not significant (Z 2 
2.46, df 3). The meta-analysis did not indicate an association between GM use 
and reduction of severe PEP (inverse variance [IV] fixed-effect pooled OR, 1.90 
[95% CI, 0.54 6.65]) (Figure 2, Table ll l). When studies were stratified by the 
duration of treatment, here was no significant reduction in severe PEP in either 
group 1 (IV fixed-effect pooled OR, 2.21 [95% CI, 0.53 9.23]; P 0.28) (Figure 
3A) or group 2 (IV fixed-effect pooled OR, 1.01 [95% CI, 0.06 16.26]; P 0.99) 
(Figure 3B). There was no significant heterogeneity in group 1 (Z 2 2.38, df 2; 
P 0.30) (Figure 3A). Only 1 study 9 in group 2 reported severe PEP, so the result 
of the heterogeneity test was unavailable (Figure 3B). 
The subgroup analysis of the case-fatality ratio of PEP is shown in Figures 3A 
and 3B. Data for the case-fatality ratio of PEP were extracted from 3 trials 8'1°'13 that 
included 1802 patients, 11 (0.6%) of whom died (GM group, 4; placebo group, 7). 
The Q test of heterogeneity of effect sizes was not significant (Z 2 0.75, df 2; P 
0.69). Moreover, there was no significant association between the use of GM and the 
reduction of the case-fatality ratio of PEP (IV fixed-effect pooled OR, 0.55 [95% CI, 
0.17 1.77]; P 0.32) (Figure 2, Table ll l). 
SECONDARY OUTCOMES 
The subgroup analysis of post-ERCP hyperamylasemia is shown in Figures 3A 
and 3B. Both post-ERCP hyperamylasemia and b ominal pain were considered as 
secondary outcomes in the meta-analysis. For post-ERCP hyperamylasemia, d ta were 
derived from 6 RCTs.  7 11,13 These trials included 2447 patients, with 851 (34.8%) 
patients having post-ERCP hyperamylasemia. Among these patients, 432 were treated 
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Table II. Jadad quality score of randomized controlled trials included in the meta-analysis. 
Withdrawals 
Year of and Jadad 
Reference Publication Randomization Blinding Dropouts Score 14 
Benini et al 7. 1985 Not mentioned Double Unclear 2 
Cavallini et al 8t 1996 Centralized Double Clearly 5 
randomization reported 
schedule 
Andriulli et apt 2002 Computer-generated Double Clearly 5 
list reported 
Andriulli et al l° t  2004 Computer-generated Double Clearly 5 
list reported 
Xiong et a111t 2006 Computer-generated Double Clearly 5 
randomized set of reported 
numbers 
Benvenuti et a112. 2006 Randomization Unclear Clearly 2 
mentioned, but reported 
method not specified 
Manes et a113t 2007 Computer-generated Double Clearly 5 
list reported 
*Abstract. 
tFull paper (complete report). 
with GM and 419 received placebo. The Q test of heterogeneity of effect sizes was not 
significant (Z 2 2.94, df 5; P 0.71). Although post-ERCP hyperamylasemia was 
noted in 32.8% (432/1318) of patients with GM and 37.1% (419/1129) of control 
patients, the results of the meta-analysis indicated no significant association between 
the use of GM and reduction of post-ERCP hyperamylasemia (IV fixed-effect pooled 
OR, 0.88 [95% CI, 0.74 1.05]; P 0.16) (Figure 2, Table Ill). 
The subgroup analysis ofpost-ERCP abdominal pain is shown in Figures 3A and 
3B. Data for post-ERCP abdominal pain were extracted from 5 RCTs, 8 11,13 which 
included 2391 patients. Two hundred seventy-six patients (11.5%) had post-ERCP 
abdominal pain; 143 were treated with GM and 133 were in the control group. The 
Q test of heterogeneity of effect sizes was significant (Z 2 11.95, df 4; P 0.02). 
Although post-ERCP abdominal pain was noted in 11.1% of the patients in the GM 
group versus 12.1% in the placebo group, the results of meta-analysis showed that 
post-ERCP there was no significant association between the use of GM and the occur- 
rence of abdominal pain as compared with placebo control (DL random-effect pooled 
OR 0.78 [95% CI, 0.49 1.25]; P 0.30) (Figure 2, Table lll). 
SENSIT IV ITY  ANALYS IS  
Sensitivity analysis of these trials was performed using 3 independent exclusion 
methods. We excluded the trials in which the allocation concealment was inadequate 
or unclear; those that were published as abstracts; and those that had aJadad score < 3.
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Table I I I .  Results of the meta-analysis and the sensitivity analysis. 
Method 
Adverse Event A* Bt 
PEP 
N 
Pooled OR (95% Cl) 0.65 
P 
Severe PEP 
N 
Pooled OR (95% Cl) 1.90 
P 
Case-fatality ratio of PEP 
N 
Pooled OR (95% CI) 0.55 
P 
Post-ERCP hyperamylasemia 
N 
Pooled OR (95% CI) 0.88 
P 
Post-ERCP abdominal pain 
N 
Pooled OR (95% CI) 0.78 
P 
2827 2391 
(0.36-1.18)  0.59 (0.30-1.16)  
0.16 0.13 
2216 1780 
(0 .54-6 .65)  2.22 (0 .53-9 .29)  
0.32 0.27 
1802 1802 
(0.17-1.77) 0.55 (0.17-1.77) 
0.32 0.32 
2447 2391 
(0.74-1.05) 0.89 (0.75-1.07) 
0.16 0.20 
2391 2391 
(0.49-1.25)  0.78 (0.49-1.25)  
0.30 0.30 
PEP = post-endoscopic retrograde cholangiopancreatography pancreatitis; OR = odds ratio; ERCP = 
endoscopic retrograde cholangiopancreatography. 
*Met&analysis including all tr ials] 13 
tSensitivity analysis in which the trials with inadequate or unclear allocation concealment, the trials 
that were published in abstract form, and the trials in which the Jadad score was <3 were excluded; all 
3 methods excluded the same trials, r,12 
The results of the 3 methods were the same; each method excluded the same 2 tri- 
als. 7,12 The overall estimates and the 95 % CIs were similar between the meta-analysis 
and the sensitivity analysis (Table l l l).  
PUBL ICAT ION B IAS  
Publication bias was assessed for all pooled ORs with 95% CIs using the Begg 
test. 27,28 The results are presented as a funnel plot of the treatment effects estimated 
from individual studies plotted on the horizontal axis (OR) against he SE of the esti- 
mate shown on the vertical axis (SE [log OR]) (Figure 4). All of the studies lay within 
the 95% CI and were uniformly distributed around the vertical axis, suggesting a
low likelihood of publication bias. 
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I I 
0.1 0.2 0.5 1.0 2.0 5.0 
OR (fixed) 
Figure 4. Funnel plot illustrating meta-analysis of the incidence of post-endoscopic 
retrograde cholangiopancreatography pancreatiUs. SE (log OR) = standard 
error of the estimate; OR = odds ratio. 
ADVERSE EVENTS 
The AEs of GM were evaluated in the current study. Three trials found various AEs 
of GM. 8,11,13 In 1 trial, 8 8 patients experienced AEs (2 in the GM group and 6 in the 
placebo group). In the GM group, 1 patient had mild nausea nd vomiting and 1 had 
self-limiting dyspnea and a hypertensive crisis. The 6 patients in the placebo group 
experienced the following AEs: nausea (2 patients), vomiting (3), hypotension (1), 
sweating (1), and fatigue (1). All of the AEs resolved without treatment. In the study 
by Xiong et al, 11 symptoms (eg, bloating, nausea, vomiting, fever) were reported in 
both groups, with no statistically significant difference between the GM group and 
the placebo group. Manes et a113 found no AEs in the GM group and concluded that 
there was no significant correlation between the use of GM and AEs. 
DISCUSSION 
Acute pancreatitis, the most frequent and serious complication of ERCP, cannot al- 
ways be avoided. 4 A drug that can prevent pancreatic injury after ERCP remains an 
unmet clinical need. Most of the ongoing attempts to minimize the occurrence and 
severity of PEP have been disappointing. Studies with calcitonin, aprotonin, nifedi- 
pine, and glucagon found no decrease in post-ERCP hyperamylasemia or pancreati- 
tis.29 32 Several studies of the long-acting somatostatin analogue octreotide have 
produced conflicting results. 33 36 Meta-analyses ofall prospective RCTs ofcorticoster- 
oids and allopurinol have also found that these agents did not prevent pancreatic in- 
jury after ERCP. 37,38 Murray et a139 found that diclofenac 100 mg administered as a 
suppository immediately after ERCP reduced the incidence of PEP (24 patients de- 
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veloped PEP, of whom 7 received rectal diclofenac and 17 received placebo [P < 
0.05]). However, this finding has not been confirmed since no additional studies of 
this diclofenac regimen have been conducted. 
Acute pancreatitis i an inflammatory process within the pancreas that may have 
systemic manifestations. The triggering event is thought o be the premature activa- 
tion of proteolytic enzymes, resulting in cellular injury and autodigestion ofpancre- 
atic tissue. 4° As a protease inhibitor and a highly diffusible molecule, GM may be 
protective against intracellular trypsin activation. Once trypsin is activated, GM may 
also play a protective role by inhibiting activation of the other proteases. 41
The activation of proteinase is one of the most important pathogeneses of pancre- 
atic injury after ERCE The efficacy of GM in preventing PEP was demonstrated in 
previous tudies. 3,s,13 In the first large-scale prospective study, which was conducted 
in Italy, Cavallini et al s found that GM significantly reduced pancreatitis after ERCP 
compared with placebo (the occurrences of PEP were 2% and 8%, respectively; P < 
0.05). Manes et a113 reported that the decrease in the incidence of PEP when GM was 
administered immediately after ERCP was similar to the decrease that was achieved 
by pre-ERCP administration. The incidence of PEP was 3.9% in the preprocedure 
administration group, 3.4% in the postprocedure administration group, and 9.4% in 
the placebo group (both, P < 0.01 vs placebo). A meta-analysis 3 published in 2000 
that included 6 studies (one ofwhich was included in the present study 7) also reported 
that patients who received GM after ERCP had a significantly lower incidence of 
PEP than the control group (1.6% vs 6.5%, respectively; P < 0.001). Favorable con- 
clusions concerning the use of GM for the prevention of post-ERCP hyperamylasemia 
and post-ERCP abdominal pain were also drawn in this meta-analysis. 
This updated meta-analysis of 7 prospective RCTs 7 13 that were published in dif- 
ferent languages evaluated the effectiveness and tolerability of GM in the prevention 
of PEP. We found that the occurrences of PEP, post-ERCP hyperamylasemia, post- 
ERCP abdominal pain, and the case-fatality ratio of PEP did not correlate with the 
prophylactic use of GM. The results of the meta-analysis indicated that GM did not 
prevent pancreatic injury after ERCE Moreover, there was no association between the 
prophylactic use of GM and AEs, although AEs were reported in 3 studies, s'11'13 We 
also evaluated the quality of these RCTs using the Jadad score, 14 and found that the 
results of meta-analysis were consistent with the sensitivity analysis. Furthermore, 
the results were also similar to the outcomes of the meta-analysis that Andriulli et al 2 
updated in 2007. The present meta-analysis and that of Andriulli et al differ in that 
ours included 3 additional RCTs, which covered more risk factors for PEP. Second, 
our study included patients with high, average, and low risk for PEP, while the other 
meta-analysis was limited to patients with average PEP risk. Therefore, the results of 
the effectiveness and tolerability of GM in the prophylaxis of PEP were supported. 
However, the differing conclusions between the present study and the arlier study 
by Andriulli et al 3 might be due to the inclusion and exclusion criteria. In the present 
study, we included only clinical RCTs, while the other study included clinical con- 
trolled trials and relied heavily on the conclusion of one clinical controlled trial s be- 
cause the other trials 7,19 21 had small sample sizes. In addition, discordance among the 
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large RCTs was recognized and ascribed to the heterogeneity of the study populations 
and to differences in experimental design (eg, patient selection, indication for ERCP, 
therapeutic maneuvers performed, and different routes of drug administration). 42 
Patient heterogeneity anddifferences in experimental design could explain the diver- 
gence of the results. The duration of GM treatment might also have contributed to the 
different outcomes; however, in the current study, subgroup analyses were conducted 
after the studies were grouped by the drug administration schedule. GM was found 
to be ineffective when administered either as a short-term (<6 hours) or a long-term 
(>6 hours) infusion (Figures 3A and 3B). This result was also in accordance with the 
findings of Masci et al. 22 
CONCLUSIONS 
No beneficial effects of GM on acute pancreatitis, the PEP death rate, or post-ERCP 
abdominal pain or hyperamylasemia were found; therefore, GM cannot be recom- 
mended for the prophylaxis of PEP. 
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